# PHAR — Pharming Group

## Status: Investigating
**Archetype:** pdufa
**Event:** EVT-2026-017
**Created:** 2026-01-19

## Thesis (2 minutes)
Pharming Group is seeking label expansion for Joenja (leniolisib) into pediatric patients (4-11 years) with APDS. Joenja is already approved for adults, reducing regulatory risk. The company is cash-flow positive with US$376M preliminary 2025 revenue. Rare disease focus with orphan drug advantages. The PDUFA date is January 31, 2026.

## Kill Screens
- [x] M-Score: -2.0 (Estimated) (PASS)
- [x] Z-Score: ~2.0 (Adjusted for Biotech) (PASS)
- [x] Market cap: $1.17B (< $50B threshold) (PASS)
- [x] PDUFA Financial Health:
    - Cash Runway: Positive cash flow (PASS)
    - Debt/Equity: 0.49 (PASS)
    - Net Cash Position: Healthy (PASS)

**v1.1 Archetype-Specific Data:**
- **PDUFA**: Form 483 with OAI: No (PASS), EMA approved: No (Review extension to Jan 2026)
- **Insider**: N/A for this archetype check
- **Activist/Spin-off**: N/A
- **Merger Arb**: N/A

## Options Analysis
**Archetype Supports Options:** Yes
**Options Viable:** No
**Reason:** Options liquidity is insufficient and spreads are too wide for a binary catalyst play.

## Scoring (Final: 9.5)

### Filter Scores
- **Catalyst:** 2.0 — Hard PDUFA date Jan 31, 2026. Extremely clear binary event.
- **Mispricing:** 1.5 — Market underestimating the value of pediatric label expansion for an already approved drug.
- **Noise Survival:** 2.0 — Cash-flow positive biotech with solid revenue base.
- **Downside Floor:** 1.5 — Strong support from existing adult Joenja and Ruconest sales.
- **Risk/Reward:** 1.5 — 2.5:1 ratio. De-risked regulatory pathway given adult approval.
- **Info Half-Life:** 1.0 — Idiosyncratic regulatory edge persists until PDUFA date.

**Base Score:** 9.5

### Adjustments
None applicable (EMA approval pending submission).

**Final Score:** 9.5

### Decision: BUY
Score 9.5 exceeds threshold 8.25. High conviction setup due to rare cash-flow positive status in PDUFA archetype.

## Key Questions
- [ ] What is the pricing impact of pediatric expansion?
- [ ] How many pediatric APDS patients are identified in the US?

## Quick Take
Solid rare-disease play with a de-risked catalyst (already approved in adults). Financials are much stronger than typical developmental biotechs.

## Links
- [Pharming IR](https://www.pharming.com/investors)
- [FDA sNDA announcement](https://www.pharming.com/news/pharming-announces-fda-acceptance-supplemental-new-drug-application-joer-leniolisib-apds)